Compare Arqit Quantum Inc (ARQQ) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arqit Quantum Inc vs Merck & Co., Inc. — how do they compare? Arqit Quantum Inc trades at $23.45 (market cap $424.79M), while Merck & Co., Inc. trades at $132.85 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 757.5× Arqit Quantum Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Arqit Quantum Inc pays none. Which is the better fit depends on your goals.
| ARQQ | MRK | |
|---|---|---|
Market Cap | $424.79M | $321.77B |
Sector | Technology | Health |
52-Week High | $58.27 | $131.84 |
52-Week Low | $11.78 | $77.60 |
Enterprise Value | $398.10M | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARQQ trades at $24.10, up 6.59% today, with a bullish technical signal from moving averages. The company shows explosive revenue growth (829% YoY in H1 2026) but remains deeply unprofitable with a -4,508% net margin. Recent news highlights quantum-safe encryption partnerships with telecom and government clients, driving investor optimism despite significant financial losses.
Outlook remains speculative with high risk/reward profile. The quantum security market offers substantial growth potential, but ARQQ must demonstrate path to profitability amid heavy operating losses. Analyst consensus is divided (50% Buy, 50% Hold), reflecting uncertainty about timeline for sustainable operations.
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arqit Quantum Inc
Arqit Quantum provides advanced cybersecurity software that uses symmetric key agreement technology. Its solutions protect networked devices and data against current and future cyber threats, including quantum attacks.
Read more on ARQQ →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
